NGM Biopharmaceuticals Inc (NGM) 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a...

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS...

Form 8-K - Current report

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a...

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023...